“The company hasmade significant investments in the platinum chromium alloy, and our success

“The company hasmade significant investments in the platinum chromium alloy, and our success with the PtCr Stent Series in Europe and other international marketshas confirmed that stent material really matters,” said Hank Kucheman, the president of Natick, Mass.-based Boston Scientific’s Cardiology, Rhythm and Vascular division. “We believe the PtCr platform sets a new standard for drug-eluting stent performance and represents the future of coronary stenting.”